The Australia & New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC) was formed in 2008 and currently consists of twelve sites across Australia and New Zealand:
Crohn’s Disease and Ulcerative Colitis are chronic, debilitating disorders of the gastrointestinal tract. ANZIBDC’s major objective is to progress knowledge and clinical practice in the field of IBD through the combination of both clinical and scientific research. In order to achieve this objective, ANZIBDC is pursuing the following goals:
Each ANZIBDC site contributes patient DNA, phenotype data and biological samples (such as blood, stool and tissue samples). By pooling these resources, ANZIBDC can undertake more complex and powerful research. The work of the ANZ Consortium will serve as a basis for contributing to international studies and collaborating with European and North American IBD consortia who are undertaking similar work.
Please visit our website for more information.